What J2H Biotech does

J2H Biotech is a South Korean clinical-stage biopharmaceutical company founded in 2014 that develops small-molecule therapeutics for rare and intractable diseases. The company operates a dual-engine business combining proprietary drug discovery and development with GMP-certified API manufacturing and CDMO services. Its R&D engine is built around the OPTIFLEX® platform, an AI-driven drug discovery system that uses multidimensional scoring of physicochemical and pharmacokinetic properties to accelerate lead identification, with sub-platforms OPTIFLEX®-SM for small molecules and OPTIFLEX®-TPD for targeted protein degradation (TPD) drugs aimed at undruggable targets.

The company's clinical pipeline spans seven candidates addressing metabolic-associated steatohepatitis (J2H-1702, a selective 11β-HSD1 inhibitor that completed Phase 2a in December 2025), idiopathic pulmonary fibrosis (J2H-2302, a multi-kinase inhibitor partnered with SK chemicals), non-small cell lung cancer (J2H-2002, an EGFR degrader via TPD), multiple sclerosis (J2H-1801, IND-approved for Phase 1), inflammatory bowel disease (J2H-1802), atopic dermatitis and osteoarthritis (J2H-2104), and solid tumors (J2H-2301). The company monetizes through a B2B sales-led model: licensing and co-development deals with pharmaceutical partners — with SK chemicals as the anchor investor-customer since 2021 — CDMO contracts at its two manufacturing facilities (the GMP-certified Ansan Plant and the multi-purpose Asan Plant with nine reactors ranging 200L to 5,000L), and proprietary API product sales including Donepezil hydrochloride, Entresto new salts, Gemigliptin new salts, L-Arginine hydrochloride, and Eltrombopag olamine.

J2H is headquartered in Suwon with an additional development R&D center in Seongnam, and has been recognized by Korean government programs including Preliminary Unicorn designation (2019), Excellent Corporate R&D Center (2021), Inno-Biz certification, and selection for the National Project on Global Rare Disease Diagnosis and Treatment Development with approximately 6 billion KRW in funding support. The company has raised roughly $37 million cumulatively across disclosed equity rounds and holds 57 Korean patent applications, 17 Korean grants, 24 PCT applications, and 35 international grants. Revenue figures are not publicly disclosed.

Name

J2H Biotech

Legal name

J2H Biotech Inc.

Website

https://j2hbio.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

J2H Biotech is a South Korean clinical-stage biopharmaceutical company developing small-molecule therapeutics for rare and intractable diseases using its proprietary OPTIFLEX® AI-driven drug discovery platform, while operating GMP-certified API manufacturing and CDMO services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Drug Discovery and CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Small molecule drug discovery
• Contract development manufacturing
• Rare disease therapeutics
• API manufacturing services
• Targeted protein degradation

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. CDMO/Contract Manufacturing Services: J2H Biotech operates two GMP-certified manufacturing facilities (Ansan and Asan plants) providing contract development and manufacturing organization (CDMO) services to pharmaceutical clients. Services include API production, patent circumvention APIs, clinical trial material manufacturing, and commercial-scale production.
2. Drug Development Licensing and Co-development: The company generates potential licensing revenue through co-development partnerships with pharmaceutical companies. J2H develops drug candidates through Phase 2a and beyond, with licensing or co-development deals with partners such as SK chemicals, with the goal of out-licensing programs or receiving milestone payments.
3. API Product Sales: The company develops and produces proprietary Active Pharmaceutical Ingredients including Donepezil hydrochloride, Entresto new salts, Gemigliptin new salts, L-Arginine hydrochloride, and Eltrombopag olamine for commercial supply to pharmaceutical clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

J2H Biotech is a bio-venture company that develops small-molecule drugs for the treatment of rare and intractable diseases using its proprietary OPTIFLEX AI-driven drug discovery platform, with seven candidates across MASH, IPF, NSCLC, multiple sclerosis, IBD, atopic dermatitis, osteoarthritis, and solid tumors. The company also operates two manufacturing facilities — a GMP-certified Ansan Plant for high-value API production and a multi-purpose Asan Plant — providing API manufacturing, patent circumvention, and CDMO (contract development and manufacturing organization) services to pharmaceutical clients under co-development and licensing partnerships.

Product overview

J2H Biotech operates as a dual-engine business with innovative drug R&D and API/CDMO manufacturing. The R&D division develops small-molecule oral therapeutics for rare and incurable diseases using the proprietary OPTIFLEX® AI-driven platform, spanning seven drug candidates (J2H-1702, J2H-2302, J2H-2002, J2H-1801, J2H-1802, J2H-2104, J2H-2301) across MASH, IPF, NSCLC, multiple sclerosis, IBD, atopic dermatitis, osteoarthritis, and solid tumors. The API division operates two manufacturing facilities: GMP-certified Ansan Plant for high-value API production and CDMO services, and Asan Plant for multi-purpose chemical synthesis and CDMO business. The company's most advanced pipeline, J2H-1702 for MASH, has completed Phase 2a clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• CDMO (Contract Development and Manufacturing Organization) Services Contract development and manufacturing organization services including API production, patent circumvention APIs, clinical trial material manufacturing, commercial-scale production, OEM, ODM, and toll manufacturing for pharmaceutical clients. Production is supported by GMP-certified Ansan Plant and Asan Plant reactors ranging from 200L to 5,000L (G/L & SUS), dryers, filters, and milling systems, with CMC documentation support.
• Proprietary Active Pharmaceutical Ingredient (API) Products Proprietary Active Pharmaceutical Ingredients developed and produced at J2H Biotech's API Division for commercial supply to pharmaceutical clients, including Donepezil hydrochloride, Entresto new salts, Gemigliptin new salts, L-Arginine hydrochloride, and Eltrombopag olamine. The company also holds a granted patent on the novel crystalline free base form of Tenofovir Disoproxil, which J2H successfully defended against invalidation challenges from 11 competing pharmaceutical companies.
• Drug Development, Co-Development, and Out-Licensing Programs Drug development programs supporting co-development partnerships and out-licensing of small-molecule drug candidates for rare and intractable diseases. J2H Biotech develops candidates through Phase 2a and beyond, then enters licensing or co-development agreements with pharmaceutical partners such as SK chemicals for assets including J2H-1702 (MASH), J2H-2302 (IPF), J2H-2002 (NSCLC), J2H-1801 (multiple sclerosis), J2H-1802 (IBD), J2H-2104 (atopic dermatitis/osteoarthritis), and J2H-2301 (solid tumors).

Quantifiable outcome

• J2H-1702 (MASH candidate): MRI-PDFF liver fat content decreased in dose-dependent and statistically significant manner vs. placebo; ALT liver function improved significantly in two high-dose groups; MRE-based liver stiffness decreased 30% or more in 10% of drug-treated patients vs. 0% in placebo; fibrosis biomarkers (Pro-C3, TIMP-1, PIIINP, HA, ELF) consistently decreased across all doses.
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Korea Health Industry Development Institute (KHIDI)minorStrategic or Co-development Partner · 23 June 2026KHIDI organized partnering sessions between Korean biotechnology firms including J2H Biotech and AstraZeneca experts at the BIO International Convention in San Diego under Project NOVA. KHIDI plans to support follow-up communication to facilitate joint R&D, building on the K-Biopharma Next Bridge initiative launched with Korea's Ministry of Health and Welfare.
• SK chemicals (SK케미칼)coreStrategic or Co-development Partner · 26 March 2026SK chemicals and J2H Biotech signed a memorandum of understanding to collaborate on new drug development focusing on MASH and IPF treatments. Both companies agreed to share research results and review data to determine the potential for joint development and commercialization. SK chemicals has been collaborating with J2H since 2021 through platform-based joint research for candidate discovery and strategic equity investment. The partnership expanded to potential co-development of J2H-1702 (MASH, Phase 2a completed) and J2H-2302 (IPF, preclinical).
• Aptis (앱티스)coreStrategic or Co-development Partner · 22 October 2025Aptis and J2H Biotech entered a collaboration for ADC (Antibody-Drug Conjugate) new drug co-development. This partnership combines Aptis's ADC platform capabilities with J2H's small molecule and TPD technologies for innovative oncology drug development.
• Samsung Seoul HospitalcoreStrategic or Co-development Partner · 15 July 2025Samsung Seoul Hospital and J2H Biotech entered a joint development agreement for BK virus (BKV) treatment targeting kidney transplant recipients and immunocompromised patients. This collaboration leverages clinical expertise and patient access to advance novel therapeutics for a rare, difficult-to-treat viral infection.
• Huons (휴온스)minorStrategic or Co-development Partner · 3 July 2017J2H Biotech partnered with Huons for the development of a novel crystalline free base form of Tenofovir Disoproxil (generic version of Gilead's Viread). J2H provided the novel crystal form patent and the parties jointly conducted clinical studies, filing for product approval on the PMS expiration date. J2H successfully defended the patent against challenges from 11 competing pharmaceutical companies.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• LegoChem Biosciences: South Korean biotech with a proprietary ADC and TPD platform (ConjuAll, TetraMAV) developing oncology therapeutics. Directly comparable to J2H on small-molecule discovery platform, TPD/ADC capability, and Korean biotech scale.
• Hanmi Pharmaceutical: Major South Korean pharma with deep small-molecule pipelines and in-house CDMO/API manufacturing across multiple plants. Comparable to J2H in combining proprietary small-molecule R&D with integrated GMP manufacturing and B2B pharmaceutical services.
• Bridge Biotherapeutics: South Korean clinical-stage biotech developing small-molecule therapies for fibrotic and inflammatory diseases, notably IPF. Closely comparable to J2H in indication overlap (IPF) and small-molecule, Korean clinical-stage biotech profile.
• Gtreebio: South Korean biotech developing small-molecule therapeutics for ophthalmology and fibrotic diseases, co-founded by J2H's current CSO. Comparable to J2H on small-molecule modality, Korean biotech scale, and rare/intractable disease focus.
• MedPacto: South Korean clinical-stage biotech focused on small-molecule oncology drug development. Comparable to J2H on small-molecule discovery, oncology pipeline programs (e.g., solid tumor candidates), and Korean clinical-stage biotech positioning.
• Bioneer: South Korean biotech with molecular diagnostics and bio-therapeutic development plus in-house manufacturing. Comparable to J2H on combined R&D and manufacturing capabilities within a Korean mid-cap biotech profile.

Broad incumbents

• Yuhan Corporation: Large South Korean pharmaceutical company with established small-molecule pipelines and active CDMO/API business. Comparable to J2H's CDMO plus proprietary drug development dual model, but at substantially greater scale and broader scope.
• HK inno.N: Mid-to-large South Korean pharmaceutical company with small-molecule development and CDMO operations. Comparable to J2H on the integrated pharma-plus-CDMO structure, though operating at a much larger and more diversified scale.
• Dong-A ST: Established South Korean pharmaceutical company with proprietary small-molecule drug pipelines and specialty manufacturing. Comparable to J2H on Korean pharma with proprietary small-molecule R&D plus manufacturing infrastructure, though at much greater commercial scale.

Emerging players

• Aptis (partner): South Korean biotech with ADC platform capabilities partnered with J2H on ADC co-development. Comparable to J2H as a Korean emerging biotech collaborating on next-generation oncology modalities, with adjacent rather than directly overlapping technology.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about J2H Biotech